Pharmacological profile ofvalsartan: apotent, orally active, nonpeptide antagonist oftheangiotensin IIAT,-receptor subtype

[1]  J. Wood,et al.  Measurement of blood pressure and heart rate by telemetry in conscious, unrestrained marmosets. , 1993, The American journal of physiology.

[2]  J. Barnes,et al.  Pharmacological profile of GR117289 in vitro: a novel, potent and specific non‐peptide angiotensin AT1 receptor antagonist , 1992, British journal of pharmacology.

[3]  W. Greenlee,et al.  In vitro pharmacology of L-158,809, a new highly potent and selective angiotensin II receptor antagonist. , 1992, The Journal of pharmacology and experimental therapeutics.

[4]  M. Ondetti.  Angiotensin Converting Enzyme Inhibitors An Overview , 1991, Hypertension.

[5]  P. Timmermans,et al.  Angiotensin II Receptor Antagonists From Discovery to Antihypertensive Drugs , 1991, Hypertension.

[6]  S. Whitebread,et al.  Nonpeptidic angiotensin II antagonists: synthesis and in vitro activity of a series of novel naphthalene and tetrahydronaphthalene derivatives. , 1991, Journal of medicinal chemistry.

[7]  J. Wood,et al.  Prolonged Angiotensin II Antagonism in Spontaneously Hypertensive Rats: Hemodynamic and Biochemical Consequences , 1991, Hypertension.

[8]  D. T. Dudley,et al.  Characterization of angiotensin II (AT2) binding sites in R3T3 cells. , 1991, Molecular pharmacology.

[9]  R. Chang,et al.  Potent, orally active imidazo[4,5-b]pyridine-based angiotensin II receptor antagonists. , 1991, Journal of medicinal chemistry.

[10]  P. Halushka,et al.  1-(carboxybenzyl)imidazole-5-acrylic acids: potent and selective angiotensin II receptor antagonists. , 1991 .

[11]  L. Pease,et al.  Angiotensin II receptor heterogeneity. , 1991, American journal of hypertension.

[12]  M. I. Steinberg,et al.  Characterization of Distinct Angiotensin II Binding Sites in Rat Adrenal Gland and Bovine Cerebellum Using Selective Nonpeptide Antagonists , 1991, Journal of cardiovascular pharmacology.

[13]  P. Timmermans,et al.  The discovery of potent nonpeptide angiotensin II receptor antagonists: a new class of potent antihypertensives. , 1990, Journal of medicinal chemistry.

[14]  S. Whitebread,et al.  Preliminary biochemical characterization of two angiotensin II receptor subtypes. , 1989, Biochemical and biophysical research communications.

[15]  B. Massie,et al.  Controlled Trial of Captopril in Chronic Heart Failure: A Rest and Exercise Hemodynamic Study , 1983, Circulation.

[16]  Pals Dt,et al.  Historical development of saralasin. , 1979 .

[17]  D. Rodbard,et al.  Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. , 1978, The American journal of physiology.

[18]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[19]  D. C. Fessler,et al.  Role of the Pressor Action of Angiotensin IIin Experimental Hypertension , 1971, Circulation research.

[20]  P. Timmermans,et al.  Pharmacology of nonpeptide angiotensin II receptor antagonists. , 1992, Annual review of pharmacology and toxicology.

[21]  P. Timmermans,et al.  Nonpeptide angiotensin II receptor antagonists: a novel class of antihypertensive agents. , 1990, Blood vessels.

[22]  S. Whitebread,et al.  Binding characteristics and vascular effects of various angiotensin II antagonists. , 1990, Journal of cardiovascular pharmacology.

[23]  P. Timmermans,et al.  Nonpeptide angiotensin II receptor antagonists. , 1990, American journal of hypertension.

[24]  J. Wood,et al.  The renin-angiotensin system : inhibitors and antagonists , 1986 .